Erdheim-Chester disease (ECD) is a multisystemic histiocytic neoplasm often identified by skeletal and visceral involvement. However, recent medical literature emphasizes the importance of recognizing atypical Erdheim-Chester disease skin lesions. Specifically, some patients develop glomeruloid haemangiomas and extensive angiomas. These lesions occur even when the classic features of POEMS syndrome are absent. Investigators have linked these findings to markedly elevated levels of vascular endothelial growth factor-A (VEGF-A).

Molecular Insights into Cutaneous ECD

Research demonstrates that MAPK-activated histiocytes drive these skin changes through a paracrine mechanism. Molecular analyses show that the histiocytes themselves harbor the activating mutations rather than the endothelial cells. Consequently, these histiocytes secrete VEGF-A, which stimulates localized blood vessel growth. This unique pathway explains why vascular proliferations appear in these patients. Furthermore, this mechanism differentiates these lesions from those caused by intrinsic vascular mutations.

Managing Erdheim-Chester Disease Skin Lesions

Notably, the presence of glomeruloid haemangiomas often suggests POEMS syndrome. However, in the context of ECD, these lesions emerge due to systemic cytokine elevations. Clinicians should therefore screen patients with atypical vascular lesions for underlying histiocytic disorders. Treatment often targets the underlying MAPK pathway using BRAF or MEK inhibitors. Monitoring VEGF-A levels may also provide insight into disease activity and treatment response.

Frequently Asked Questions

What are the common Erdheim-Chester disease skin lesions?

The most common skin findings are periorbital xanthelasma-like lesions. However, atypical vascular lesions like glomeruloid haemangiomas can occur due to high VEGF-A levels.

How is VEGF-A related to Erdheim-Chester disease?

Histiocytes with MAPK mutations produce VEGF-A. This factor acts on nearby blood vessels to cause abnormal proliferation, leading to angiomas in the skin.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Razanamahery J et al. Glomeruloid haemangioma in Erdheim-Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor-A levels. Br J Haematol. 2026 Jun 19. doi: 10.1111/bjh.70627. PMID: 42318765.


2. Fardet L et al. Glomeruloid haemangioma: a possible consequence of elevated VEGF in POEMS and Erdheim-Chester disease. Br J Dermatol. 2018;179(6):1414-1415.


3. Diamond EL et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-492.